These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Söderhäll S, Ljunggren Ö, Åström E. Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348 [Abstract] [Full Text] [Related]
3. Reduced spinal bone mineral density in adolescents of an Ultra-Orthodox Jewish community in Brooklyn. Taha W, Chin D, Silverberg AI, Lashiker L, Khateeb N, Anhalt H. Pediatrics; 2001 May; 107(5):E79. PubMed ID: 11331729 [Abstract] [Full Text] [Related]
8. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL. Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105 [Abstract] [Full Text] [Related]
11. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Land C, Rauch F, Travers R, Glorieux FH. Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117 [Abstract] [Full Text] [Related]
12. Correlation of scoliotic curvature with Z-score bone mineral density and body mass index in patients with osteogenesis imperfecta. Watanabe G, Kawaguchi S, Matsuyama T, Yamashita T. Spine (Phila Pa 1976); 2007 Aug 01; 32(17):E488-94. PubMed ID: 17762282 [Abstract] [Full Text] [Related]
13. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F. J Bone Miner Res; 2015 Dec 01; 30(12):2150-7. PubMed ID: 26059976 [Abstract] [Full Text] [Related]
14. Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity. Nobile S, Grand RJ, Pappa HM. Eur J Gastroenterol Hepatol; 2018 Apr 01; 30(4):471-476. PubMed ID: 29438136 [Abstract] [Full Text] [Related]
15. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Bone; 2006 Oct 01; 39(4):901-6. PubMed ID: 16730480 [Abstract] [Full Text] [Related]
16. Diagnosis of Recurrent Fracture in a Pediatric Cohort. Fiscaletti M, Coorey CP, Biggin A, Briody J, Little DG, Schindeler A, Munns CF. Calcif Tissue Int; 2018 Nov 01; 103(5):529-539. PubMed ID: 29943187 [Abstract] [Full Text] [Related]
17. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Pediatrics; 2003 May 01; 111(5 Pt 1):1030-6. PubMed ID: 12728084 [Abstract] [Full Text] [Related]
18. Individualized evaluation of lumbar bone mineral density in children with cerebral palsy. Duran I, Katzmann J, Martakis K, Stark C, Semler O, Schoenau E. Arch Osteoporos; 2018 Nov 05; 13(1):120. PubMed ID: 30397843 [Abstract] [Full Text] [Related]
19. Vertebral bone mass, size, and volumetric density in women with spinal fractures. Duan Y, Parfitt Am, Seeman E. J Bone Miner Res; 1999 Oct 05; 14(10):1796-802. PubMed ID: 10491228 [Abstract] [Full Text] [Related]
20. Bone mineral density of the lumbar spine of Brazilian children and adolescents aged 6 to 14 years. Fonseca AS, Szejnfeld VL, Terreri MT, Goldenberg J, Ferraz MB, Hilário MO. Braz J Med Biol Res; 2001 Mar 05; 34(3):347-52. PubMed ID: 11262585 [Abstract] [Full Text] [Related] Page: [Next] [New Search]